Treatment of pigmentary disorders using picosecond laser in Asian patients: A meta‐analysis and systematic review

2021 ◽  
Author(s):  
Wenxin Dong ◽  
Na Wang ◽  
Xiaohai Yuan ◽  
Wei Zhang
Keyword(s):  
Systematic Review ◽  
Meta Analysis ◽  
Picosecond Laser ◽  
Asian Patients ◽  
Pigmentary Disorders

Preoperative Platelet to Lymphocyte Ratio as a Prognostic Factor for Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis

2020 ◽  
Vol 37 (6) ◽  
pp. 447-455
Author(s):  
Romualdas Riauka ◽  
Povilas Ignatavicius ◽  
Giedrius Barauskas
Keyword(s):  
Systematic Review ◽  
Pancreatic Cancer ◽  
Prognostic Factor ◽  
Meta Analysis ◽  
Disease Free Survival ◽  
Platelet To Lymphocyte Ratio ◽  
Resectable Pancreatic Cancer ◽  
Lymphocyte Ratio ◽  
Asian Patients ◽  
Hazard Ratios

<b><i>Introduction:</i></b> Various inflammatory markers have been investigated for a prognostic role in patients with resectable pancreatic cancer. However, the value of preoperative platelet to lymphocyte ratio (PLR) remains controversial. We performed a systematic review and meta-analysis of PLR as a preoperative prognostic factor for resectable pancreatic cancer. <b><i>Material and Methods:</i></b> Systematic literature search was conducted for studies assessing PLR influence as a preoperative prognostic factor in resectable pancreatic cancer patients. Random-effects model was applied for pooling hazard ratios and 95% confidence intervals related to overall survival (OS) and disease-free survival (DFS). <b><i>Results:</i></b> Fourteen articles with 2,743 patients were included in the study. According to the analysis, high PLR had no correlation with decreased OS. Due to high heterogeneity among studies, subgroup analysis was performed. Better OS was associated with low PLR in Asian patients, patients with mixed type of operation performed, and patients with preoperative PLR ≤150. Low PLR was associated with significantly better DFS. <b><i>Conclusions:</i></b> PLR is a predictive factor of better DFS in patients with resectable pancreatic cancer. However, available evidence does not support PLR as a reliable prognostic factor for OS.

“When offered to participate”: A systematic review and meta-analysis of patient agreement to participate in cancer clinical trials.

2020 ◽  
Vol 38 (29_suppl) ◽  
pp. 92-92
Author(s):  
Joseph M. Unger ◽  
Dawn L. Hershman ◽  
Cathee Till ◽  
Lori M. Minasian ◽  
Raymond U Osarogiagbon ◽  
...  
Keyword(s):  
Systematic Review ◽  
Decision Making ◽  
Clinical Trials ◽  
Meta Analysis ◽  
Trial Participation ◽  
Participation Rates ◽  
Patient Decision Making ◽  
Asian Patients ◽  
Patient Decision ◽  
Black Patients

92 Background: Patient participation in clinical trials (CTs) is vital for knowledge advancement and outcomes improvement. The rate of CT participation for adult cancer patients is between 5%-8%; many CTs fail due to poor accrual. Although patient decision-making is a common focus of studies examining barriers to CT participation, the rate of trial participation for patients actually offered a CT is unknown. Methods: We conducted a systematic review and meta-analysis using PubMed, Web of Science, and Ovid Medline search engines to identify studies over 20 years (1/1/2000-1/1/2020) that examined CT participation. Studies must have been conducted in the United States and specified the number of patients offered a CT and the number enrolled. We conducted a meta-analysis of single proportions using random effects. Rates were examined for both treatment trials and cancer control (CC) studies. We also compared the rates of enrollment between Black, Hispanic, and Asian patients versus White patients. Clinical care setting (academic vs community) was examined as a potential moderator. Results: We screened 3,241 unique citations and identified 35 (30 treatment and 5 CC) studies among which n = 9,759 patients were offered CT participation. Overall, 55.0% (95% CI: 49.4%-60.5%) of patients offered a CT agreed to enroll. Trial participation rates did not differ between treatment (55.0%, 95% CI: 48.9%-60.9%) and CC trials (55.3%, 95% CI: 38.9%-71.1%, p = .98); however, participation rates were significantly higher at academic centers (58.4%, 95% CI: 52.2%-64.5%) versus community centers (45.0%, 95% CI: 34.5%-55.7%, p = .04). In common studies, Black patients agreed to participate at similar rates (58.4%, 95% CI: 46.8%-69.7%) compared to White patients (55.1%, 95% CI: 44.3%-65.6%, p = .88). Results were also similar comparing White versus Hispanic or Asian patients. The main reasons for non-participation were treatment choice or lack of interest. Conclusions: More than half of all cancer patients who are offered CTs do participate; results were consistent between major race/ethnicity groups. This finding upends several conventional beliefs about cancer clinical trial participation, including that Black patients are less likely to agree to participate and that patient decision-making is the primary barrier to participation. Policies and interventions to improve CT participation should focus more on modifiable systemic structural and clinical barriers, such as improving access to existing trials and broadening trial eligibility.

scholarly journals Efficacy and safety of Dabigatran vs. Rivaroxaban among Asians with non-valvular atrial fibrillation：Protocol for a systematic review and meta-analysis

2021 ◽  
Author(s):  
Li Jia ◽  
Mingming Zhou ◽  
Li Sun ◽  
Luhai Yu ◽  
Xiangyan He
Keyword(s):  
Systematic Review ◽  
Ischemic Stroke ◽  
Meta Analysis ◽  
Oral Anticoagulants ◽  
Cochrane Library ◽  
Efficacy And Safety ◽  
Systemic Embolism ◽  
China National Knowledge Infrastructure ◽  
Asian Patients ◽  
Meta Analyses

Abstract Atrial fibrillation(AF) increases the risk of ischemic stroke and systemic embolism in patients. Moreover, Asian patients with AF are more likely to have ischemic stroke than non-Asian patients. Oral anticoagulants could effectively prevent thrombotic events. Dabigatran and Rivaroxaban are two most commonly used novel oral anticoagulants (NOACs) in Asia, but those clinicial studies in relation with them are mostly in American and European countries. Therefore, whether there are differences between Dabigatran and Rivaroxaban among Asian patients with AF in terms of efficacy and safety is still unknown. This systematic review and meta-analysis will mainly assess clinical efficacy and safety of Dabigatran versus Rivaroxaban in Asian patients with AF by a pooled analysis. We will follow the PRISMA (preferred reporting items for systematic reviews and meta-analyses) and the reporting MOOSE (Meta-analyses of Observational Studies in Epidemiology) when performing this study. Then Cochrane Library,Web of Science, PubMed and China national knowledge infrastructure will be searched for eligible retrospective investigation that report the efficacy and safety outcomes of AF patients who utilised Dabigatran or Rivaroxaban for stroke prevention in Asian countries. The abovementioned database will be comprehensively searched from inception to September 30, 2019 to locate all potentially eligible studies. Outcome measures will include safety and efficacy indicators. Safety indicators include intracranial hemorrhage, major bleeding and gastrointestinal bleeding. Efficacy indicators include systemic embolism and stroke. New evidence for clinical profile of Dabigatran versus Rivaroxaban in AF patients will be provided for decision-making of Asian patients.PROSPERO registration number: CRD42020156197

Systematic review and meta-analysis on the rate of postoperative venous thromboembolism in orthopaedic surgery in Asian patients without thromboprophylaxis

2011 ◽  
Vol 98 (10) ◽  
pp. 1356-1364 ◽  
Author(s):  
B. Kanchanabat ◽  
W. Stapanavatr ◽  
S. Meknavin ◽  
C. Soorapanth ◽  
C. Sumanasrethakul ◽  
...  
Keyword(s):  
Systematic Review ◽  
Venous Thromboembolism ◽  
Orthopaedic Surgery ◽  
Meta Analysis ◽  
Asian Patients

scholarly journals Risk of colorectal cancer in Asian patients with ulcerative colitis: a systematic review and meta-analysis

2017 ◽  
Vol 2 (4) ◽  
pp. 269-276 ◽  
Author(s):  
Sawan Bopanna ◽  
Ashwin N Ananthakrishnan ◽  
Saurabh Kedia ◽  
Vijay Yajnik ◽  
Vineet Ahuja
Keyword(s):  
Colorectal Cancer ◽  
Systematic Review ◽  
Ulcerative Colitis ◽  
Meta Analysis ◽  
Asian Patients
Sign in / Sign up

Export Citation Format

Share Document